Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Carcinoma, Renal Cell 77Kidney Neoplasms 23Prostatic Neoplasms 22Neoplasm Metastasis 13Colorectal Neoplasms 10Neoplasms 8Melanoma 7Carcinoma, Transitional Cell 6Breast Neoplasms 6Urinary Bladder Neoplasms 5Stomach Neoplasms 5Glioblastoma 5Carcinoma, Non-Small-Cell Lung 5Pancreatic Neoplasms 4Ovarian Neoplasms 4Carcinoma, Hepatocellular 4Uterine Cervical Neoplasms 3Squamous Cell Carcinoma of Head and Neck 3Sarcoma 3Urologic Neoplasms 2Triple Negative Breast Neoplasms 2Myeloproliferative Disorders 2Multiple Myeloma 2Hereditary leiomyomatosis and renal cell cancer 2Hematologic Neoplasms 2Financial Stress 2Esophageal Neoplasms 2Endometrial Neoplasms 2Colonic Neoplasms 2Cholangiocarcinoma 2

Interventions

atezolizumab 1Specimen Handling 1Magnetic Resonance Spectroscopy 1Immunoglobulin G 1GSK 1363089 1Erlotinib Hydrochloride 1Disulfides 1Contrast Media 1Biopsy 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Papillary renal cell carcinoma, sporadic × Bevacizumab × Genitourinary × Clear all
NCT04981509 2026-06-03

Testing of Bevacizumab, Erlotinib, and Atezolizumab in Combination for Advanced-Stage Kidney Cancer

National Cancer Institute (NCI)

Phase 2 Recruiting
65 enrolled
Genitourinary

Hereditary leiomyomatosis and renal cell cancer, Papillary renal cell carcinoma, sporadic, Carcinoma, Renal Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡